SEC Form 4 · accession 0001104659-16-107417
Corvus Pharmaceuticals, Inc. · CRVS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard A Miller M.D.
Officer — President and CEO · Director
Period of report
Mar 22, 2016
Accepted (ET)
Mar 24, 2016 · 4:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001626971
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $15.00 | Mar 22, 2016 | A | 500,000 | A | — | Mar 22, 2026 | Common Stock | 500,000 | 500,000 | D |
Explanation of responses
- F1The option is immediately exercisable in full or in part. The underlying shares subject to the option vest as to one-forty-eighth (1/48th) of the shares in successive, equal monthly installments measured from March 22, 2016, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.